Avanos Medical Inc (AVNS)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Avanos Medical Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
52-Week Range
Current price 25.00 $ — 99% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
0/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 2.4%
- Exp. sales growth 3Y > 5% 2.7%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 2.7%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 6
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -25.6%
- ROCE > 15% -6.8%
- Expected return > 10% 6.5%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 0.8% failed
- More than 10% revenue growth is expected for the coming year 4.2% failed
- Share count grows by less than 3% a year -0.6% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 8.1% failed
- Gross margin at 40% or higher and without meaningful erosion 49.8% failed
- Goodwill from acquisitions does not grow faster than revenue 36.8% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 730 m passed
- Return on capital at 15% or higher, or up versus two years ago -6.8% failed
- Insiders hold at least 10% or are net buyers 3.3% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 44.0% below the current price.
- Consensus
- Hold
- Analyst Ratings
- 1
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1.00 | 1.00 – 1.00 | 710 | 6.4% | 1 |
| 12/31/2027 | 1.25 | 1.25 – 1.25 | 740 | 25.0% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.22 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -8.64 | -3,933.20 | 180 | 3.60 | -221.20 | 58 | 53 |
| 2025: Q1 | 0.14 | – | 168 | 0.80 | 3.90 | 26 | 19 |
| 2025: Q2 | -1.64 | -4,321.10 | 175 | 1.90 | -43.90 | 7 | -4 |
| 2025: Q3 | -0.03 | -132.70 | 178 | 4.30 | -0.80 | 14 | 7 |
| 2025: Q4 | 0.08 | – | 181 | 0.70 | 2.00 | 28 | 21 |
| 2026: Q1 | 0.11 | -22.10 | 182 | 8.80 | 2.80 | -12 | -17 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 566 | -69 | 40 | 0.85 | 189 | 1,103 | 2,072 |
| 2017 | 612 | -16 | 79 | 1.69 | 144 | 1,215 | 2,196 |
| 2018 | 652 | 35 | 58 | 1.22 | -146 | 1,297 | 1,833 |
| 2019 | 698 | -5 | -46 | -0.96 | -75 | 1,265 | 1,800 |
| 2020 | 715 | 71 | -27 | -0.57 | -3 | 1,257 | 1,673 |
| 2021 | 745 | 87 | 6 | 0.13 | 87 | 1,271 | 1,604 |
| 2022 | 684 | 42 | 51 | 1.07 | 91 | 1,291 | 1,787 |
| 2023 | 673 | 65 | -62 | -1.33 | 32 | 1,236 | 1,692 |
| 2024 | 688 | 40 | -392 | -8.52 | 101 | 829 | 1,154 |
| 2025 | 701 | -62 | -68 | -1.46 | 75 | 778 | 1,074 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Avanos Medical, Inc., ein Medizintechnikunternehmen, bietet Medizinproduktlösungen in Nordamerika, Europa, im Nahen Osten, in Afrika, im asiatisch-pazifischen Raum und in Lateinamerika an.
| Employees | 2,287 |
|---|---|
| Headquarters | Alpharetta, GA |
| Address | 5405 Windward Parkway, 30004 Alpharetta, United States |
| Phone | 844 428 2667 |
| Website | avanos.com |
| IPO Date | 21. Oct 2014 |
| ISIN | US05350V1061 |
Management
| Name | Title | Birth Year |
|---|---|---|
| David C. Pacitti M.B.A. | CEO & Director | 1966 |
| Scott Michael Galovan | Senior VP & CFO | 1979 |
| Sigfrido Delgado | Senior Vice President of Operations | 1977 |
| Jason M. Pickett | Vice President of Corporate Finance & Treasurer | 1972 |
| John Joseph Hurley | Principal Accounting Officer & Controller | – |
| Siobhan Smyth | VP & Chief Information Officer | – |
| Jonathan Turner | VP and Chief Ethics & Compliance Officer | – |
| John S. Fischer Esq. | VP, Head of Legal & Secretary | 1958 |
| Katrine Kubis | Vice President of Corporate Communications & Community Relations | – |
| Jamie Handler | Vice President of Global Marketing | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 27. Jul 2026 | Delgado Sigfrido | SVP, Operations | Other | 54,886 | 25.00 | 1,372,150 |
| 27. Jul 2026 | Delgado Sigfrido | SVP, Operations | Other | 54,886 | 0.00 | – |
| 27. Jul 2026 | Delgado Sigfrido | SVP, Operations | Other | 55,741 | 25.00 | 1,393,525 |
| 27. Jul 2026 | Galovan Scott Michael | SVP, Chief Financial Officer | Other | 96,121 | 25.00 | 2,403,025 |
| 27. Jul 2026 | Galovan Scott Michael | SVP, Chief Financial Officer | Other | 96,121 | 0.00 | – |
| 27. Jul 2026 | Galovan Scott Michael | SVP, Chief Financial Officer | Other | 135,596 | 25.00 | 3,389,900 |
| 27. Jul 2026 | Pacitti David | Chief Executive Officer | Other | 444,730 | 25.00 | 11,118,250 |
| 27. Jul 2026 | Pacitti David | Chief Executive Officer | Other | 444,730 | 0.00 | – |
| 27. Jul 2026 | Pacitti David | Chief Executive Officer | Other | 322,194 | 25.00 | 8,054,850 |
| 27. Jul 2026 | Shimer Julie Ann | Director | Other | 50,090 | 25.00 | 1,252,250 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.